Company Deep Dive

Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.

View Deep Dive

BMY.MX

Strong BuyFull HouseREMOVE

Bristol-Myers Squibb Company · Healthcare · United States · $134.4B · Avg Vol: $33K/d

100
StockRank
Get insider-trade alerts
Q
75
V
70
M
85
P/E (TTM)
14.1x
ROE
46.6%
D/E
2.0x
Dividend %
3.9%
Dir. Trades · 180d
None →
Buybacks · 180d
None →
AI CONVICTION THESIS

While the dividend yield is attractive, the company faces significant headwinds from the GLP-1 pivot, which threatens its legacy cardiovascular and metabolic revenue streams. Despite their scale, the lack of a clear, aggressive pipeline advantage in the next-generation metabolic space makes this a defensive 'value trap' rather than an asymmetric winner.

COMPANY DESCRIPTION

Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing innovative medicines for serious diseases in oncology, immunology, and cardiovascular areas. Its competitive moat is built on a robust R&D pipeline, strong intellectual property protection for blockbuster drugs, and a global commercial presence. BMY is a major pharmaceutical innovator, continually investing in groundbreaking science and strategic acquisitions to deliver transformative medicines.

FINANCIAL SUMMARY (MXN)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue791.5B771.7B828.2B826.4B1.4%843.4B854.8B825.4B-0.1%
EPS (MXN)50.9366.53-75.6259.505.3%77.47———
Shares2.1B2.0B2.0B2.0B-1.9%2.0B———
Debt698.2B711.0B877.9B808.3B5.0%772.5B———
Equity532.6B504.6B280.1B316.8B-15.9%————
Op CF224.0B237.7B260.5B242.7B2.7%219.2B———
Inv CF-18.2B-39.4B-366.1B-70.9B—————
Fin CF-290.9B-161.5B87.9B-177.4B—————
Loading 1Y...
PRICE (1Y)+6.9%
61.6762.8764.0865.2866.48Jul 22Aug 12Sep 1
SMA 50SMA 200

Close
$65.90
RSI (14)
84.7
52W High
$67.24
From 52W High
1.0%

SCORE BREAKDOWN

Quality
75
ROIC
16.8%87.8
ROE
46.6%97.1
GP/Assets
39.1%78.0
Op. Margin
34.4%93.7
FCF/Assets
14.3%92.0
Piotroski
894.5
Int. Cover
5.9x55.2
D/E Ratio
2.02x5.9
Current Ratio
1.53x27.4
Value
70
P/E (TTM)
14.1x76.7
EV/EBITDA
7.0x83.7
P/FCF
10.5x82.4
P/B
7.0x18.9
P/S
2.6x61.5
Div Yield
3.9%82.0
Momentum
85
52W High %
98%97.7
RS 6M
14%77.3
SMA 50/200
1.06x70.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
153%88.7

FUNDAMENTALS

Market Cap
$134.4B
P/E (Forward)
—
Gross Margin
71.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BMY.MX are excluded.

TickerCompanyMkt CapStockRankSignal
BMY.MXBristol-Myers Squibb Company(you)$134.4B—Hold
SNYSanofi$107.4B95Strong Buy
G1SK34.SAGSK plc$101.2B91Strong Buy
NVON.MXNovo Nordisk A/S$200.8B93Strong Buy
PFEPfizer Inc.$159.4B88Strong Buy
AMGNAmgen Inc.$233.8B84Strong Buy
4578.TOtsuka Holdings Co., Ltd.$40.0B94Strong Buy
ROP.SWRoche Holding AG$353.1B87Strong Buy
GILDGilead Sciences, Inc.$180.6B73Buy
4503.TAstellas Pharma Inc.$26.6B98Strong Buy

Peer medians: ROE 2.9% · P/E 24.4x · Gross margin 52.5%

Bristol-Myers Squibb Company (BMY.MX): Stock Score Summary

Bristol-Myers Squibb Company (BMY.MX) has a MoatMap StockRank of 100/100 based on Quality (75/100), Value (70/100), and Momentum (85/100) factor scores. The current signal is STRONG BUY. While the dividend yield is attractive, the company faces significant headwinds from the GLP-1 pivot, which threatens its legacy cardiovascular and metabolic revenue streams. Despite their scale, the lack of a clear, aggressive pipeline advantage in the next-generation metabolic space makes this a defensive 'value trap' rather than an asymmetric winner.

Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing innovative medicines for serious diseases in oncology, immunology, and cardiovascular areas. Its competitive moat is built on a robust R&D pipeline, strong intellectual property protection for blockbuster drugs, and a global commercial presence. BMY is a major pharmaceutical innovator, continually investing in groundbreaking science and strategic acquisitions to deliver transformative medicines.

Key Financial Metrics

Price$65.90
Market Cap$134.4B
P/E (TTM)14.08
Price/Book7.04
Return on Equity46.6%
Return on Invested Capital16.8%
Debt/Equity2.02x
Gross Margin71.7%
Operating Margin34.4%
Revenue Growth5.7%
Dividend Yield3.9%
Free Cash Flow$12.8B

Bristol-Myers Squibb Company operates in the Drug Manufacturers - General industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Bristol-Myers Squibb Company’s (BMY.MX) StockRank?
MoatMap’s StockRank for Bristol-Myers Squibb Company (BMY.MX) is 100/100, with a Strong Buy signal. It is a composite of Quality (75), Value (70), and Momentum (85) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Bristol-Myers Squibb Company have an economic moat?
Bristol-Myers Squibb Company (BMY.MX) has a Quality factor score of 75/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Bristol-Myers Squibb Company a buy, hold, or sell?
MoatMap’s current signal for Bristol-Myers Squibb Company (BMY.MX) is Strong Buy, based on a StockRank of 100/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Bristol-Myers Squibb Company in?
Bristol-Myers Squibb Company (BMY.MX) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry (United States).
Browse all ranked stocksBMY.MX deep dive reportAI ChampionsHow we score stocksSense-check another stock